

Press Release

Apogenix to Present at J.P. Morgan Healthcare Conference

Heidelberg, Germany, Dec. 15, 2015 – Apogenix, a next generation immuno-oncology company, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 11, 2016, at 4:00 p.m. PST at the Westin St. Francis Hotel.

“We are excited to be one of the few companies that were selected by J.P. Morgan to present at the most important healthcare conference of the year,” said Thomas Hoeger. “We have significantly advanced our immuno-oncology pipeline and are expecting final data from our clinical trial with lead drug candidate APG101 in myelodysplastic syndromes.”

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany.

Contact

Thomas Hoeger, Ph.D., CEO
Apogenix GmbH
Phone: +49 (6221) 58 60 80
E-Mail: contact@apogenix.com
Web: www.apogenix.com

Media Contacts

USA:
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1 (212) 845 4272
matt.middleman@russopartnersllc.com

Europe:
Raimund Gabriel
MC Services AG
Phone: +49 (89) 210 228 30
raimund.gabriel@mc-services.eu